Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Magnetic resonance imaging is a powerful tool in preclinical research of diseases with associated neuroinflammation, as it allows high-resolution imaging without harmful ionizing radiation. The development of targetable iron oxide contrast agents, such as microparticles of iron oxide (MPIO), has greatly enhanced molecular MRI for superior detection of target molecules. Cell adhesion molecules (CAMs) are upregulated early in neuroinflammation on the luminal side of activated endothelial cells within the blood-brain barrier, making them a highly accessible target. Targeting MPIO with CAM antibodies has improved the early detection of neuropathologies in preclinical models, as well as providing further insight into disease progression and mechanisms. This chapter highlights the uses of molecular MRI, specifically CAM-targeted MPIO, for investigating multiple sclerosis, stroke, epilepsy, and brain cancer and how the advances made in these preclinical models have the potential to be transferred to other neuropathologies and tissues.

Original publication

DOI

10.1007/978-3-031-23661-7_3

Type

Chapter

Book title

Progress in Inflammation Research

Publication Date

01/01/2023

Volume

91

Pages

91 - 117